CD38 and neoplasm: In GCV control mice, PD-L1 inhibition had no impact on mRNA levels of Cd206, Cd38, Cd80 and Il-1β, highlighting the relevance of tumour biology and systemic impact of cancer on the side effects of PD-L1 inhibitors.